Abstract:In the past decade, treatments targeting the immune system have revolutionized the cancer treatment field. Therapies such as immune checkpoint inhibitors have been approved as first-line treatment in a variety of solid tumors such as melanoma and non-small cell lung cancer while other therapies, for instance, chimeric antigen receptor (CAR) lymphocyte transfer therapies, are still in development. Although promising results are obtained in a small subset of patients, overall clinical efficacy of most immunotherapeutics is limited due to intertumoral heterogeneity and therapy resistance. Therefore, prediction of patient-specific responses would be of great value for efficient use of costly immunotherapeutic drugs as well as better outcomes. Because many immunotherapeutics operate by enhancing the interaction and/or recognition of malignant target cells by T cells, in vitro cultures using the combination of these cells derived from the same patient hold great promise to predict drug efficacy in a personalized fashion. The use of two-dimensional cancer cell lines for such cultures is unreliable due to altered phenotypical behavior of cells when compared with the in vivo situation. Three-dimensional tumor-derived organoids, better mimic in vivo tissue and are deemed a more realistic approach to study the complex tumor–immune interactions. In this review, we present an overview of the development of patient-specific tumor organoid-immune co-culture models to study the tumor-specific immune interactions and their possible therapeutic infringement. We also discuss applications of these models which advance personalized therapy efficacy and understanding the tumor microenvironment such as: (1) Screening for efficacy of immune checkpoint inhibition and CAR therapy screening in a personalized manner. (2) Generation of tumor reactive lymphocytes for adoptive cell transfer therapies. (3) Studying tumor–immune interactions to detect cell-specific roles in tumor progression and remission. Overall, these onco-immune co-cultures might hold a promising future toward developing patient-specific therapeutic approaches as well as increase our understanding of tumor–immune interactions.

Revolutionizing immune research with organoid-based co-culture and chip systems

Engineering the Immune Microenvironment into Organoid Models

Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies

In vitro immunity: an overview of immunocompetent organ-on-chip models

Immune organoids: from tumor modeling to precision oncology

Organoids as a tool to study homeostatic and pathological immune–epithelial interactions in the gut

Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients

Stem Cells and Organoid Technology in Precision Medicine in Inflammation: Are We There Yet?

Organoids as an Enabler of Precision Immuno-Oncology

Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment

Cancer organoid co-culture model system: Novel approach to guide precision medicine

Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment

Microfluidic Organoids-on-a-Chip: Quantum Leap in Cancer Research

Organoids and organ-on-chip technology for investigating host-microorganism interactions

Model Organoids: Integrated Frameworks for the Next Frontier of Healthcare Advancements

Towards the development of human immune-system-on-a-chip platforms

Disease modelling in human organoids

Organoid Models of Tumor Immunology

Cancer modeling meets human organoid technology

Biofabrication Directions in Recapitulating the Immune System-on-a-Chip